LatticePoint

Last week LatticePoint was at the World Orphan Drug Congress Europe. It was great to have the opportunity to talk about #EUHTA, #JCA, #PICO and their particular considerations for #OrphanDrugs. As discussed during these days, the importance of involving the patients and hearing their voices in the whole drug development and access process can't be overstated. From LatticePoint we wanted to particularly thank to, Dravet Syndrome Foundation Spain, Fundacion Española de Enfermedades Raras, MYOS, Funcolehf, ANSEDH · Asociación Nacional del Síndrome de Ehlers-Danlos e Hiperlaxitud, TURNER CATALUNYA Associació Síndrome de Turner de Catalunya, and all the other patient associations that told us how is to live with a rare disease and what they need from us. If you did not have time to meet with us, please do not hesitate to reach out to Ignacio Fargas Gutiérrez, Elżbieta Szulc or Jordi Hernández PhD MBA! #MarketAccess #OrphanDrugs #RareDiseases

How to generate value in a disease where there’s high disease burden but few or no highly objective endpoints? European payer archetypes value differently objective and patient-reported outcomes. Therefore, one needs a good mix to successfully communicate and defend product value vs. payers for a European launch. Check out how differently patient reported outcome are valued across the EU-5 and how this translated into different perception of abrocitinib endpoints in severe atopic dermatitis. In atopic dermatitis, remission (e.g., measured by EASI100) and safety (e.g., hospitalisation) are objective endpoints, while patient-reported outcome such as pain are more subjective. Of note, patient-reported outcome measures need to be patient-relevant, disease-relevant, and validated.     Would you like to assess your mix of endpoints? Get in touch with us!   Stay tuned for more insights and assessments! #LatticePoint #insights #strategy

LatticePoint team is at #Stockholm at #BioEurope! If you want to discuss the best strategy to get your drug to the market, or assess the right P&R for your product, do not hesitate to reach out! Ignacio Fargas Gutiérrez and Jordi Hernández PhD MBA will be happy to discuss with you! #biotech #pharma #innovation #marketaccess

You might think that HTA outcomes are more predictable in domains such as cancer treatments, where endpoints are well established and highly objective, for example overall survival, progression-free survival, and safety. But, have you ever wondered how payers may assess value of therapies in a disease, which mainly impacts quality of life and where the main endpoints are patient-reported outcomes? Let's have a look at atopic dermatitis, a chronic skin disease where this is exactly the case. #latticepoint #insights #strategy

In our latest post, we shared our Strategy Canvas Analysis for Jemperli® (dostarlimab) in endometrial cancer (https://lnkd.in/exfrc3y9). But… how did we build it? 🤔 Discover the steps behind creating this valuable tool and how it highlights payer priorities, unmet needs, and product differentiation. Stay tuned for more insights! #LatticePoint #insights #strategy

The PD-1 story is far from over!                                                                             You might think that with anti-PD-1 antibodies being available for over a decade and more anti-PD-1/L1 checkpoint inhibitors approved on a regular basis (current count in Europe is 7), we have seen it all. Yet, these therapies are still transforming the landscape of cancer treatment, delivering improved outcomes for patients in an ever-widening range of cancers. There is no end in sight.   Exciting news for patients with advanced or recurrent endometrial cancer: They will soon have three checkpoint inhibitors to enhance their standard chemotherapy regimen of paclitaxel and carboplatin: Jemperli has beaten Keytruda and Imfinzi to the market and received the rating of major benefit (erheblicher Zusatznutzen) in Germany - a recognition that only about 10 products have achieved since the AMNOG process began.                                                                            What kind of product achieves this? Dive into our strategy canvas for dostarlimab (below) and see how it uniquely addresses the unmet needs identified by payers and aligns perfectly with their preferences.   Stay tuned for more insights and assessments! #LatticePoint #Germany #GBA

If you have read out post 🏋♂️ "𝘏𝘰𝘸 𝘨𝘺𝘮 𝘴𝘶𝘣𝘴𝘤𝘳𝘪𝘱𝘵𝘪𝘰𝘯𝘴 𝘪𝘯𝘴𝘱𝘪𝘳𝘦𝘥 𝘱𝘢𝘺𝘦𝘳𝘴?" You will be able to answer: 𝐖𝐡𝐚𝐭 𝐢𝐬 𝐭𝐡𝐞 𝐦𝐚𝐢𝐧 𝐮𝐧𝐜𝐞𝐫𝐭𝐚𝐢𝐧𝐭𝐲 𝐚𝐝𝐝𝐫𝐞𝐬𝐬𝐞𝐝 𝐛𝐲 𝐚 𝐜𝐨𝐧𝐝𝐢𝐭𝐢𝐨𝐧𝐚𝐥 𝐜𝐨𝐧𝐭𝐢𝐧𝐮𝐚𝐭𝐢𝐨𝐧 𝐚𝐠𝐫𝐞𝐞𝐦𝐞𝐧𝐭❓ Looking forward to checking your answers❗ https://lnkd.in/dGRykk8S #MarketAccess #LifeSciences #MEA #Pharmaceuticals #HTA #Innovation

We're #hiring a new HTA Statistician in Barcelona, Catalonia. Apply today or share this post with your network.

We're #hiring a new HTA Statistician in Geneva, Geneva. Apply today or share this post with your network.

While some new drugs 💊 reach the market with a clear price and reimbursement strategy, some more cutting-edge medicines 💪 can reach the market with certain uncertainties, in terms of their performance 🤒 or financial impact 📈 . How, can you maximize the value of your medicine while ensuring the proper coverage for patients and controlling its financial impact on payers ❓ 🔍 𝗨𝗻𝗹𝗲𝗮𝘀𝗵𝗶𝗻𝗴 𝘁𝗵𝗲 𝗽𝗿𝗶𝗰𝗲 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗼𝗳 𝘆𝗼𝘂𝗿 𝗱𝗿𝘂𝗴 Even with a great clinical trial and fantastic data, payers are faced with uncertainties when negotiating the price and reimbursement of innovative drugs. One of the tools that healthcare payers in Europe use to manage this uncertainty are the Managed Entry Agreements (MEAs). 🌟 𝗕𝘂𝘁 𝗳𝗶𝗿𝘀𝘁, 𝘄𝗵𝗮𝘁 𝐚𝐫𝐞 𝐌𝐚𝐧𝐚𝐠𝐞𝐝 𝐄𝐧𝐭𝐫𝐲 𝐀𝐠𝐫𝐞𝐞𝐦𝐞𝐧𝐭𝐬? MEAs are private agreements between European healthcare payers and firms launching new pharmaceutical products. The objective of these agreements is to ensure the proper coverage for the patients while managing potential uncertainties around the financial impact of the drug, its performance or proper use. 🔍 𝗛𝗼𝘄 𝗱𝗼 𝘄𝗲 𝗱𝗼 𝗶𝘁? At LatticePoint Consulting, we can help you navigate this complex environment through our extensive experience and proprietary methodologies. By leveraging our historic market access expertise, knowledge of how payers think, analog product analysis, and value-based pricing, we develop an actionable strategic roadmap to guide your decision making to implement non-linear pricing structures. 📞 𝗟𝗲𝘁'𝘀 𝗖𝗼𝗻𝗻𝗲𝗰𝘁! Interested in learning more about this innovative pricing strategy? Fill out the following form or contact via email at jordi.hernandez@latticepointconsulting.com: Our team is ready to assist. #Pharmaceuticals #MarketAccess #PricingStrategy #Innovation #Healthcare #LatticePointConsulting #ManagedEntryAgreements #MEAs